Improved ticagrelor antiplatelet effect on discontinuation of phenytoin

Area of Science:

• Cardiology
• Pharmacology
• Drug Interactions

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is vital after coronary stent placement to prevent thrombotic events.
• Ticagrelor is a P2Y12 inhibitor commonly used in DAPT, but its efficacy can be affected by drug-drug interactions.
• Phenytoin is an antiepileptic drug known to induce hepatic cytochrome P450 enzymes, which are involved in drug metabolism.

Observation:

• A case study involving a patient with coronary artery disease who underwent percutaneous coronary intervention and received ticagrelor for antiplatelet therapy.
• The patient was also taking phenytoin, a known inducer of drug metabolism.
• Platelet aggregation studies revealed diminished antiplatelet inhibition by ticagrelor while the patient was on both medications.

Findings:

• Discontinuation of phenytoin led to improved platelet inhibition by ticagrelor.
• This suggests a clinically significant drug-drug interaction where phenytoin enhances the metabolism of ticagrelor.
• The interaction results in reduced P2Y12 receptor inhibition, potentially compromising the antiplatelet effect.

Implications:

• The combination of ticagrelor and phenytoin may reduce the effectiveness of antiplatelet therapy in patients post-percutaneous coronary intervention.
• Healthcare providers should be aware of this interaction and adhere to manufacturer recommendations to avoid co-administration of ticagrelor with strong cytochrome P450-3A4 inducers like phenytoin.
• This finding underscores the importance of medication reconciliation and awareness of drug metabolism pathways in managing patients on antiplatelet therapy.